JP4716994B2 - ＤｅｓＡフィブリンを含有する悪性腫瘍抑制剤 - Google Patents

ＤｅｓＡフィブリンを含有する悪性腫瘍抑制剤 Download PDF

Info

Publication number
JP4716994B2
JP4716994B2 JP2006528841A JP2006528841A JP4716994B2 JP 4716994 B2 JP4716994 B2 JP 4716994B2 JP 2006528841 A JP2006528841 A JP 2006528841A JP 2006528841 A JP2006528841 A JP 2006528841A JP 4716994 B2 JP4716994 B2 JP 4716994B2
Authority
JP
Japan
Prior art keywords
fibrin
fibrinogen
des
cells
malignant tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2006528841A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2006001523A1 (ja
Inventor
博文 千賀
彩霞 李
永玲 万
立水 常
Original Assignee
東菱薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東菱薬品工業株式会社 filed Critical 東菱薬品工業株式会社
Priority to JP2006528841A priority Critical patent/JP4716994B2/ja
Publication of JPWO2006001523A1 publication Critical patent/JPWO2006001523A1/ja
Application granted granted Critical
Publication of JP4716994B2 publication Critical patent/JP4716994B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006528841A 2004-06-24 2005-06-24 ＤｅｓＡフィブリンを含有する悪性腫瘍抑制剤 Active JP4716994B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006528841A JP4716994B2 (ja) 2004-06-24 2005-06-24 ＤｅｓＡフィブリンを含有する悪性腫瘍抑制剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004213635 2004-06-24
JP2004213635 2004-06-24
JP2006528841A JP4716994B2 (ja) 2004-06-24 2005-06-24 ＤｅｓＡフィブリンを含有する悪性腫瘍抑制剤
PCT/JP2005/012174 WO2006001523A1 (ja) 2004-06-24 2005-06-24 Des A フィブリンを含有する悪性腫瘍抑制剤

Publications (2)

Publication Number Publication Date
JPWO2006001523A1 JPWO2006001523A1 (ja) 2008-04-17
JP4716994B2 true JP4716994B2 (ja) 2011-07-06

Family

ID=35781928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006528841A Active JP4716994B2 (ja) 2004-06-24 2005-06-24 ＤｅｓＡフィブリンを含有する悪性腫瘍抑制剤

Country Status (10)

Country Link
US (2) US20060088519A1 (ko)
EP (1) EP1762242B1 (ko)
JP (1) JP4716994B2 (ko)
KR (1) KR101032249B1 (ko)
CN (1) CN1972706B (ko)
AU (1) AU2005257508A1 (ko)
CA (1) CA2566991A1 (ko)
HK (2) HK1100359A1 (ko)
RU (1) RU2358754C2 (ko)
WO (1) WO2006001523A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2217267B1 (en) * 2007-12-14 2016-05-25 Tobishi Pharmaceutical Co., Ltd. An agent for reducing a side effect of an anticancer drug
KR20100135312A (ko) * 2008-04-24 2010-12-24 디 오스트레일리언 내셔널 유니버시티 합성 중합체의 방사성 표지화 방법
CA3049856C (en) * 2017-01-13 2021-10-26 Tobishi Pharmaceutical Co., Ltd. Neutrophil activation regulator

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE447579B (sv) * 1985-04-01 1986-11-24 Biopool Ab Solubiliserbar, fibrinbaserad komposition och anvendning av kompositionen vid bestemning av fibrinolysparametrar
JP4116683B2 (ja) * 1997-02-28 2008-07-09 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 徐放性局所送達製剤
US20020131935A1 (en) * 1998-04-10 2002-09-19 Fisher Darrell R. Fibrin carrier compound for treatment of disease
US6610043B1 (en) * 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
CN1176719C (zh) * 2001-01-05 2004-11-24 江苏安格药业有限公司 降纤酶在制备体内止血药中的应用
AUPR920301A0 (en) 2001-11-30 2001-12-20 Polychip Pharmaceuticals Pty Ltd Neurologically-active compounds
CN1432406A (zh) * 2002-12-20 2003-07-30 周宇 蛇毒蛋白水解酶在制药中的应用

Also Published As

Publication number Publication date
US20090018062A1 (en) 2009-01-15
KR101032249B1 (ko) 2011-05-02
HK1105091A1 (en) 2008-02-01
AU2005257508A1 (en) 2006-01-05
WO2006001523A1 (ja) 2006-01-05
JPWO2006001523A1 (ja) 2008-04-17
EP1762242A1 (en) 2007-03-14
US8481047B2 (en) 2013-07-09
US20060088519A1 (en) 2006-04-27
CN1972706B (zh) 2012-03-21
EP1762242B1 (en) 2012-07-11
CA2566991A1 (en) 2006-01-05
HK1100359A1 (en) 2007-09-21
EP1762242A4 (en) 2009-09-30
RU2006145902A (ru) 2008-08-10
RU2358754C2 (ru) 2009-06-20
KR20070026846A (ko) 2007-03-08
CN1972706A (zh) 2007-05-30

Similar Documents

Publication Publication Date Title
Zhang et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway
Sonnenberg et al. Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction
US20060003932A1 (en) Method for promoting neovascularization
AU2003255290A1 (en) Use of erythropoietin
JP2006506321A (ja) 血管透過性亢進を阻害する方法
AU2001259519A1 (en) Method for promoting neovascularization
Al Heialy et al. T cell–induced airway smooth muscle cell proliferation via the epidermal growth factor receptor
JPH0449246A (ja) 賢疾患治療剤
JP4716994B2 (ja) ＤｅｓＡフィブリンを含有する悪性腫瘍抑制剤
KR101777414B1 (ko) 줄기세포 및/또는 전구세포의 활성화제
TWI482629B (zh) 下泌尿道疾病治療劑及下泌尿道症狀改善劑
KR19990087825A (ko) 조직 인자 응고계 억제제 함유 혈관 신생 저해제
CN114269362A (zh) 促进血管生成的方法
JP4673309B2 (ja) バトロキソビンを含有する悪性腫瘍局所浸潤抑制剤
CN113559245A (zh) 替度鲁肽用于制备治疗心肌缺血再灌注损伤药物中的应用
Shimoda et al. A protective effect of Sivelestat from ischemia/reperfusion injury in a porcine hepatectomy model
KR100847979B1 (ko) 바트록소빈을 함유하는 악성종양 국소 침윤억제제
Papageorgiou et al. Healing of Myocardial Infarction
JP2008506754A (ja) 急性の肝臓損傷における保護剤としてのアンフィレグリンの使用
KR20120029770A (ko) 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110322

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110329

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4716994

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250